KBC Group NV Sells 579,068 Shares of DexCom, Inc. (NASDAQ:DXCM)

KBC Group NV decreased its stake in DexCom, Inc. (NASDAQ:DXCM) by 58.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 417,688 shares of the medical device company’s stock after selling 579,068 shares during the quarter. KBC Group NV’s holdings in DexCom were worth $32,483,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in DXCM. Jennison Associates LLC raised its position in DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after purchasing an additional 6,544,102 shares during the last quarter. Westfield Capital Management Co. LP raised its holdings in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after buying an additional 876,739 shares during the last quarter. Two Sigma Advisers LP boosted its position in DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock worth $76,659,000 after buying an additional 739,000 shares during the period. Intech Investment Management LLC grew its holdings in DexCom by 2,083.0% during the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock worth $25,967,000 after acquiring an additional 369,587 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in DexCom by 53.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 989,740 shares of the medical device company’s stock valued at $66,352,000 after acquiring an additional 345,114 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on DXCM shares. Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and upped their price target for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Oppenheimer lowered their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Raymond James reduced their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Finally, JPMorgan Chase & Co. raised their price target on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $99.29.

DexCom Trading Down 1.4 %

Shares of DexCom stock opened at $87.53 on Tuesday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a 50 day moving average price of $79.50 and a two-hundred day moving average price of $76.88. The stock has a market capitalization of $34.19 billion, a PE ratio of 52.41, a price-to-earnings-growth ratio of 2.23 and a beta of 1.12.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.30% of the stock is currently owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.